-
-
-
-
-
-
-
Lilly acquires three infectious disease companies for up to $3.83 billion
-
-
-
-
-
-
-
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
-
-
-
-
-
-
-
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
-
-
-
-
-
-
-
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
-
-
-
-
-
-
-
Morgan Stanle on Eli Lilly (LLY): 'We see three potential scenarios for REDEFINE4'
-
-
-
-
-
-
-
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
-
-
-
-
-
-
-
Lilly to Acquire Adverum Biotechnologies
-
1,161,489 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

